# The ARRIVE guidelines 2.0: author checklist

## The ARRIVE Essential 10

These items are the basic minimum to include in a manuscript. Without this information, readers and reviewers cannot assess the reliability of the findings.

| Item | Recommendation | Section/line number, or reason for not reporting |
|------|----------------|--------------------------------------------------|
| **Study design** | For each experiment, provide brief details of study design including: a. The groups being compared, including control groups. If no control group has been used, the rationale should be stated. b. The experimental unit (e.g. a single animal, litter, or cage of animals). | Each experiment set control groups, see section "Materials and methods" |
| **Sample size** | a. Specify the exact number of experimental units allocated to each group, and the total number in each experiment. Also indicate the total number of animals used. b. Explain how the sample size was decided. Provide details of any a priori sample size calculation, if done. | Section "Materials and methods-Nude mouse xenografts" Line 203-204 The exact value in each experimental group is not stated, Section "Materials and methods-Nude mouse xenografts" Line 203-204 |
| **Inclusion and exclusion criteria** | a. Describe any criteria used for including and excluding animals (or experimental units) during the experiment, and data points during the analysis. Specify if these criteria were established a priori. If no criteria were set, state this explicitly. b. For each experimental group, report any animals, experimental units or data points not included in the analysis and explain why. If there were no exclusions, state so. c. For each analysis, report the exact value of n in each experimental group. | Including criteria, section "Materials and methods-Nude mouse xenografts" Line 203-204 There were exclusions in each group, Section "Materials and methods-Nude mouse xenografts" Line 203-204 We set the sample size following the method of the reference, section "References" line 525-526 |
| **Randomisation** | a. State whether randomisation was used to allocate experimental units to control and treatment groups. If done, provide the method used to generate the randomisation sequence. b. Describe the strategy used to minimise potential confounders such as the order of treatments and measurements, or animal/cage location. If confounders were not controlled, state this explicitly. | A computer based random order generator was used to allocate experimental units to control and treatment groups. |
| **Blinding** | Describe who was aware of the group allocation at the different stages of the experiment (during the allocation, the conduct of the experiment, the outcome assessment, and the data analysis). | Two different investigators were involved in the experiment who was unaware of the group allocation during different stages of experiment |
| **Outcome measures** | a. Clearly define all outcome measures assessed (e.g. cell death, molecular markers, or behavioural changes). b. For hypothesis-testing studies, specify the primary outcome measure, i.e. the outcome measure that was used to determine the sample size. | Section "Materials and methods-Nude mouse xenografts" Line 207-213 The primary outcome of this experiment is the measurement of Ki-67 nuclear markers and the section "Materials and methods-Nude mouse xenografts" Line 207-213 |
| **Statistical methods** | a. Provide details of the statistical methods used for each analysis, including software used. b. Describe any methods used to assess whether the data met the assumptions of the statistical approach, and what was done if the assumptions were not met. | See section "Image, data processing and Statistical analysis" Line 253-263 No other methods were used to assess the data |
| **Experimental animals** | a. Provide species-appropriate details of the animals used, including species, strain and substrain, sex, age or developmental stage, and, if relevant, weight. b. Provide further relevant information on the provenance of animals, health/immune status, genetic modification status, genotype, and any previous procedures. | Section "Materials and methods-Nude mouse xenografts" Line 203-204 None |
| **Experimental procedures** | For each experimental group, including controls, describe the procedures in enough detail to allow others to replicate them, including: a. What was done, how it was done and what was used. b. When and how often. c. Where (including detail of any acclimatisation periods). d. Why (provide rationale for procedures). | Section "Materials and methods-Nude mouse xenografts" and "Materials and methods-ICH" Line 203-223 Section "Materials and methods-Nude mouse xenografts" Line 204-210 Housed in an isolator-immunodeficient It is a common used procedure reported in related articles. |
| **Results** | For each experiment conducted, including independent replications, report: a. Summary/descriptive statistics for each experimental group, with a measure of variability where applicable (e.g. mean and SD, or median and range). b. If applicable, the effect size with a confidence interval. | See each figure in this study See each figure in this study |
The Recommended Set

These items complement the Essential 10 and add important context to the study. Reporting the items in both sets represents best practice.

| Item                                | Recommendation                                                                                                           | Section/line number, or reason for not reporting |
|--------------------------------------|--------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------|
| **Abstract**                         | Provide an accurate summary of the research objectives, animal species, strain and sex, key methods, principal findings, and study conclusions. | Section "Abstract", Line 34-64                   |
| **Background**                       | a. Include sufficient scientific background to understand the rationale and context for the study, and explain the experimental approach.  
   b. Explain how the animal species and model used address the scientific objectives and, where appropriate, the relevance to human biology. | Section "Introduction", Line 70-129               |
| **Objectives**                       | Clearly describe the research question, research objectives and, where appropriate, specific hypotheses being tested.      | Section "Footnote-Ethical Statement", Line 448-455 |
| **Ethical statement**                | Provide the name of the ethical review committee or equivalent that has approved the use of animals in this study, and any relevant licence or protocol numbers (if applicable). If ethical approval was not sought or granted, provide a justification. | Housing in a standard environment.                |
| **Housing and husbandry**            | Provide details of housing and husbandry conditions, including any environmental enrichment.                               | None                                             |
| **Animal care and monitoring**       | a. Describe any interventions or steps taken in the experimental protocols to reduce pain, suffering and distress.  
   b. Report any expected or unexpected adverse events.  
   c. Describe the humane endpoints established for the study, the signs that were monitored and the frequency of monitoring. If the study did not have humane endpoints, state this. | None                                             |
| **Interpretation/scientific implications** | a. Interpret the results, taking into account the study objectives and hypotheses, current theory and other relevant studies in the literature.  
   b. Comment on the study limitations including potential sources of bias, limitations of the animal model, and imprecision associated with the results. | See section "Discussion", Line 325-434            |
| **Generalisability/translation**     | Comment on whether, and how, the findings of this study are likely to generalise to other species or experimental conditions, including any relevance to human biology (where appropriate). | This research was performed to illustrate human glioma cells' biology directly. |
| **Protocol registration**            | Provide a statement indicating whether a protocol (including the research question, key design features, and analysis plan) was prepared before the study, and if and where this protocol was registered. | A protocol was prepared before the study without registration. |
| **Data access**                      | Provide a statement describing if and where study data are available.                                                    | Data access                                      |
| **Declaration of interests**         | a. Declare any potential conflicts of interest, including financial and non-financial. If none exist, this should be stated.  
   b. List all funding sources (including grant identifier) and the role of the funder(s) in the design, analysis and reporting of the study. | Section "Footnote-Conflicts of Interest", Line 445-446 |

Article information: https://dx.doi.org/10.21037/atm-21-2944

www.ARRIVEguidelines.org